Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

New Strategies Needed for TKI Resistance in EGFR+ Lung Cancer

June 1st 2019

The development of tyrosine kinase inhibitors has revolutionized the treatment of EGFR-mutant non–small cell lung cancer in recent years, but new strategies are needed to overcome resistance mechanisms that promote disease recurrence.

Pembrolizumab OS Rates Continue to Impress in NSCLC at 5 Years

June 1st 2019

After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.

Dr. Stinchcombe on the Benefit of Alectinib in ALK+ NSCLC

June 1st 2019

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the benefit of alectinib in the treatment of patients with ALK-positive non–small cell lung cancer.

Dr. Levy Discusses the Outlook for Oncogene-Driven NSCLC

May 30th 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the outlook for patients with oncogene-driven non–small cell lung cancer.

Langer Lends Insight on Transformed NSCLC Landscape

May 30th 2019

Corey J. Langer, MD, highlights how precision medicine has emerged in the treatment of patients with non–small cell lung cancer via targeted therapies and checkpoint inhibitors.

Dr. Bazhenova on Sequencing Beyond Progression in EGFR-Mutant NSCLC

May 30th 2019

Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses sequencing beyond progression on osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC

May 29th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of durvalumab in stage III non–small cell lung cancer.

Dr. Clarke Compares TKIs in EGFR+ NSCLC

May 29th 2019

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, compares EGFR TKIs in EGFR-positive non–small cell lung cancer.

Dr. Antonia on the Promise of Immunotherapy in NSCLC

May 29th 2019

Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses the promise of immunotherapy in patients with non–small cell lung cancer.

FDA Approves NovoTTF-100L Plus Chemo for Malignant Pleural Mesothelioma

May 24th 2019

The FDA has approved the NovoTTF-100L System in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma.

Osimertinib at Lower Dose Effective in EGFR-Mutant NSCLC With Leptomeningeal Metastases

May 24th 2019

Myung-Ju Ahn, MD, discusses the results from the AURA LM trial and the next steps that need to be taken in order to confirm the efficacy that was seen with the lower dose of osimertinib in patients with EGFR-mutant non–small cell lung cancer with leptomeningeal metastases.

Dr. Langer Discusses the Use of NGS in NSCLC

May 23rd 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the use of next-generation sequencing in non–small cell lung cancer.

Therapies Moving Though Pipeline for Rare Mutations in NSCLC

May 23rd 2019

Sai-Hong I. Ou, MD, PhD, discusses the status of different mutations in lung cancer and the work being done to bring clinically meaningful treatments to the space.

Targeting Mesothelin May Yield Results in Hard-to-Treat Solid Tumors

May 22nd 2019

Mesothelin, a protein found on cell surfaces and in serum, has emerged as a promising target for immunotherapy-based treatment approaches for several malignancies with poor prognoses and limited treatment options. Investigating novel approaches to optimize delivery and identifying combinations of agents to synergistically improve therapeutic response will be the next steps in bringing mesothelin-targeted therapies into the clinical setting.

Liquid Biopsies: Complementary Tool in Detecting Driver Mutations in NSCLC

May 22nd 2019

Sai-Hong I. Ou, MD, highlights the conveniences of liquid biopsies relative to tissue biopsies, as well as current drawbacks to their use in detecting targetable alterations in lung cancer.

Dr. Levy on the Benefits of Liquid Biopsies in NSCLC

May 22nd 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the benefits of liquid biopsies in non–small cell lung cancer.

Meta-Analysis Sheds Light on Treatment-Related AEs for PD-1 and PD-L1 Inhibitors

May 22nd 2019

Two in 3 patients treated with PD-1 or PD-L1 inhibitors experienced at least 1 AE and 1 in 7 patients experienced at least 1 grade ≥3 AE, according to a systematic review and meta-analysis of clinical trials and study updates published through December 15, 2018.

Dr. Xia on the Frontline Treatment Landscape of ALK-Positive NSCLC

May 22nd 2019

Bing Xia, MD, assistant professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the frontline treatment landscape of ALK-positive non–small cell lung cancer (NSCLC).

Addressing Questions Left Unanswered by PACIFIC in Stage III NSCLC

May 22nd 2019

Lyudmila A. Bazhenova, MD, discusses the phase III PACIFIC trial and clinical scenarios that warrant further investigation in the field of stage III non–small cell lung cancer.

Navigating Frontline Therapy and Treatment Beyond Progression in NSCLC

May 21st 2019

Bing Xia, MD, discusses the latest immunotherapy developments in nonsquamous non–small cell lung cancer, as well as sequencing strategies for patients with ALK-positive disease.